301507SZSE

Announcement on Progress of Second Phase Share Repurchase by Centralized Bidding

✨ AI Summary

Hangzhou Minsheng Pharmaceutical Co., Ltd. announces the progress of its second share repurchase. As of July 31, 2026, 2,320,000 shares were repurchased, representing 0.65% of total share capital, for a total cost of RMB 34,152,462. The repurchase plan aims to use funds for equity incentives.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 301507

Securities Abbreviation: Minsheng Health

Announcement No.: 2026-033

Hangzhou Minsheng Pharmaceutical Co., Ltd.

Announcement on Progress of Second Phase Share Repurchase by Centralized Bidding

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.

Key Information Prompt:

● Progress of the second phase repurchase plan: As of July 31, 2026, Hangzhou Minsheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has cumulatively repurchased 2,320,000 shares through a dedicated securities account for repurchases, via centralized bidding, accounting for 0.65% of the Company's total share capital. The highest transaction price was RMB 15.67 per share, the lowest transaction price was RMB 11.77 per share, and the payment amount was RMB 34,152,462 (excluding transaction fees).

I. Basic Information on Share Repurchase

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.